the consolidated financial statements of the Company and its subsidiaries for the first quarter ended 31st March 2020. The Company reported a consolidated loss (attributable to equity holders of the
exchange rate for Q120 was Baht/USD 31.29, Q119 was Baht/USD 31.61 (and Q419 was Baht/USD 30.28). The offshore subsidiaries income statements are translated at the average rate for the quarter, (for their
subsidiaries increased Baht 79.27 million from profit sharing from investment in BBF. 4. Property, plant and equipment increased Baht 88.58 million, mostly from the adoption of new financial reporting standards
% VS NTA financial statements for the period 1. VNG and subsidiaries trade among related companies. 25 Feb. 2020 43,000,000.00 0.701% as at 31 Dec.2019 2. Vanachai Panel Industries Co., Ltd. uses the
) Transaction Size% VS NTA financial statements for the period 1. VNG and subsidiaries trade among related companies. 25 Feb. 2020 43,000,000.00 0.701% as at 31 Dec. 2019 2. Vanachai Panel Industries Co., Ltd
Release Date Value (Baht) Transaction Size% VS NTA financial statements for the period 1. VNG and subsidiaries trade among related companies. 25 Feb. 2020 43,000,000.00 0.701% as at 31 Dec. 2019 2. Vanachai
August 11, 2020 Subject: Management’s Discussion and Analysis for the second Quarter of 2020 To: The President The Stock Exchange of Thailand (SET) DOD Biotech Public Company Limited and its subsidiaries
Company Limited and its subsidiaries (“the Company”) reported consolidated revenues of Baht 277.3 million, decreased by 42.3% compared to the same quarter last year, majorly due to the Covid-19 pandemic
financial statements, including the consolidated financial statements of the Company and its subsidiaries for the third quarter and nine month period ended 30th September 2019. The Company reported
business strategy and enhance marketing strategy for both domestic and international market to achieve more targeted customers. For the three-month period 2019, Subsidiaries can reduce the cost of sales, by